Beta-thalassemia intermedia in a Brazilian patient with-101 (C > T) and codon 39 (C > T) mutations.

Sao Paulo Med J

Centro de Biologia Molecular Estrutural e Engenharia Genética, Hemocentro, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.

Published: January 2003

Context: We verified molecular alterations in a 72-year-old Brazilian male patient with a clinical course of homozygous beta-thalassemia intermedia, who had undergone splenectomy and was surviving without regular blood transfusions. The blood cell count revealed microcytic and hypochromic anemia (hemoglobin = 6.5 g/dl, mean cell volume = 74 fl, mean cell hemoglobin = 24 pg) and hemoglobin electrophoresis showed fetal hemoglobin = 1.3%, hemoglobin A2 = 6.78% and hemoglobin A = 79.4%.

Objective: To identify mutations in a patient with the symptoms of beta-thalassemia intermedia.

Design: Molecular inquiry into the mutations possibly responsible for the clinical picture described.

Setting: The structural molecular biology and genetic engineering center of the Universidade Estadual de Campinas, Campinas, Brazil.

Procedures: DNA extraction was performed on the patient's blood samples. The polymerase chain reaction (PCR) was done using five specific primers that amplified exons and the promoter region of the beta globin gene. The samples were sequenced and then analyzed via computer programs.

Results: Two mutations that cause the disease were found: -101 (C > T) and codon 39 (C > T).

Conclusions: This case represents the first description of -101 (C > T) mutation in a Brazilian population and it is associated with a benign clinical course.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11108612PMC
http://dx.doi.org/10.1590/s1516-31802003000100007DOI Listing

Publication Analysis

Top Keywords

beta-thalassemia intermedia
8
clinical course
8
hemoglobin
6
intermedia brazilian
4
brazilian patient
4
patient with-101
4
with-101 codon
4
mutations
4
codon mutations
4
mutations context
4

Similar Publications

The role of miR-129-5p in regulating γ-globin expression and erythropoiesis in β-thalassemia.

Hum Mol Genet

December 2024

College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, 88 Jiaotong Road, Taijiang District, Fuzhou 350004, China.

The regulation of γ-globin expression is crucial due to its beneficial effects on diseases like β-thalassemia and sickle cell disease. B-cell lymphoma/leukemia 11A (BCL11A) is a significant suppressor of γ-globin, and microRNAs (miRNAs) targeting BCL11A have been shown to alleviate this suppression. In our previous high-throughput sequencing, we identified an 11.

View Article and Find Full Text PDF

Extramedullary hematopoiesis is a phenomenon that occurs in conditions of ineffective bone marrow function. In the context of thalassemias, extramedullary hematopoiesis is more frequently observed in beta-thalassemia intermedia patients, with thoracic paravertebral extramedullary hematopoiesis being relatively common. However, extramedullary hematopoiesis-related pleural effusion is a rare occurrence.

View Article and Find Full Text PDF

Background: Patients with betathalassemia have higher risk of various metabolic disturbances. The literature presents conflicting results about the patterns of abnormal lipid profile among patients with betathalassemia. This systematic review aimed to assess dyslipidemia patterns among patients with betathalassemia when compared with healthy individuals.

View Article and Find Full Text PDF

To investigate the short-term and long-term efficacy and safety of thalidomide in the treatment of intermediate and severe β-thalassemia. We analyzed patients with intermediate and severe β-thalassemia treated at our hospital from February 2019 to February 2024. Patients who received treatment for more than 3 months were included.

View Article and Find Full Text PDF

Background: Thalassemia is a chronic inherited disease with the potential for serious clinical and psychological effects. In the case of thalassemia, a cure is not currently accessible, and lifelong treatment is required. Health-related quality of life (HRQoL) is considered a crucial health outcome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!